Editas Medicine Company
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Industry:
Atrificial Vectors and Immune Cells
Last Funding Type:
Post-IPO Equity
Funding Status:
IPO
Estimated Revenue:
$1M to $10M
Total Funding:
656600000
Investors Number:
17
Headquarters:
Cambridge, Massachusetts, United States
Last Funding Date:
2021-01-21
Founded Date:
2013-01-01
Employee Number:
101-250